EGFR and familial pancreatic carcinoma: We tested if monensin would synergize with and/or sensitize pancreatic cancer cells to the currently used first-line chemotherapeutic drugs, such as gemcitabine and EGFR targeted inhibitor erlotinib, to inhibit pancreatic cancer cell proliferation.